Paolo Roazzi

TL;DR: EUROCARE-3 as mentioned in this paper analyzed the survival of 1815584 adult cancer patients diagnosed from 1990 to 1994 in 22 European countries and found that survival was highest in northern Europe (Sweden, Norway, Finland and Iceland), and fairly good in central-southern Europe (France, Switzerland, Austria and Spain).

TL;DR: The collection, standardisation and checking of cancer survival data included in the EUROCARE-4 database suggest satisfactory data quality that has improved since EUROCare-3, and methods for estimating relative survival are described.

TL;DR: Comparison of quality indicators for the EUR OCARE-3 database with earlier EUROCARE databases indicates that data quality and standardisation have improved, and overall European survival for each cancer site and for all cancers combined were calculated combining country-specific survival figures.

TL;DR: This work provides survival estimates for clinically relevant haematological malignancies (HM), using the International Classification of Diseases for Oncology 3, by country, gender and age in Europe, and finds that population based survival by morphological sub-type is important for measuring outcomes of HM management.

TL;DR: Both the completeness of primary data and the accuracy of stage coding need to be improved in order for CRs to fulfil their expanding roles in cancer control, as well as fully exploiting the stage information provided by EUROCARE CRs.